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Objective: Popliteal artery aneurysms can be treated endovascularly with less perioperative morbidity compared with open
repair. To evaluate suitability of the endovascular technique and the clinical results of this treatment, we analyzed a
prospective cohort of consecutive popliteal aneurysms referred to a tertiary university vascular center.
Methods: All popliteal artery aneurysms between June 1998 and June 2004 that measured >20 mm in diameter were
analyzed for endovascular repair. Anatomic suitability was based largely on quality of the proximal and distal landing
zone as determined by angiography. Endovascular treatment was performed by using a nitinol-supported expanded
polytetrafluoroethylene lined stent graft introduced through the common femoral artery.
Results:We analyzed 67 aneurysms in 57 patients. Ten aneurysms (15%) were excluded from endovascular repair, or from
any repair at all, for various reasons. The remaining 57 (85%) were treated endovascularly, of which 5 were treated
emergently for acute ischemia. During a mean 24-month follow-up, 12 stent grafts (21%) occluded. Primary and
secondary patency rates were 80% and 90% at 1 year, and 77% and 87% at 2 years of follow-up. Postoperative treatment
with clopidogrel proved to be the only significant predictor for success.
Conclusions: Endovascular repair of a popliteal artery aneurysm is feasible. Changes in the material used and the addition
of clopidogrel may improve patency rates. ( J Vasc Surg 2005;41:561-7.)Popliteal artery aneurysms (PAA) account for most pe-
ripheral aneurysms. They are potentially dangerous, with a
5-year cumulative risk for complications 68%.1 The most
common complications are acute thrombosis, with occlusion
of the aneurysm, and distal embolization. As a result, acute
ischemia may occur and will lead to limb loss in 40% of
patients.2 In addition, chronic distal embolization of small
mural thrombi can lead to progressive occlusion of tibial and
peroneal arteries, resulting in chronic or acute limb ischemia.
To prevent these severe complications, elective treat-
ment is advocated.2-4 Whether small and asymptomatic
aneurysms should be treated is still a point of debate.5,6
Nevertheless, most authors consider a cutoff point diame-
ter of 20 mm a criterion for treatment, and some treat even
smaller aneurysms when mural thrombus is present.1,4,6,7
Open surgical treatment with a venous bypass graft is
still the treatment of choice for most surgeons. Patency
rates of these reconstructions depend mainly on the quality
of the peroneal and tibial arteries, the type of bypass mate-
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doi:10.1016/j.jvs.2004.12.055rial, and whether the reconstruction was performed for
acute ischemia or in the elective setting.2,3,8,9
The first endovascular repair of a PAA, performed with
a homemade device, was reported in 1994 by Marin.10
Thereafter, several case reports and relatively small series
have been published describing the endovascular treatment
of PAA (Table I).
Advantages of the endovascular treatment include the
minimally invasive character of the procedure, with only a
small incision in the groin, minimal morbidity, and a shorter
operation time and hospital stay.11 A particular problem asso-
ciated with this technique is that the stent graft crosses the
knee joint. Repetitive stress on the device in this bending zone
may lead to complications, including kinking, fracture of the
stent-graft material, and occlusion.11
This study describes the results of the largest worldwide
series of PAA treated with a single type of endovascular stent
graft and analyses the predictive value of different variables on
stent-graft occlusion.
METHODS
Between June 1998 and June 2004, all consecutive
PAAs referred to University Medical Center Groningen, a
tertiary center, that measured more than 20 mm in diame-
ter on duplex ultrasound scanning were analyzed for endo-
vascular treatment. Two types of aneurysms were included:
1. Aneurysms in patients who did not presentwith acute limb
ischemia. In these patients, angiography was performed to
determine anatomic suitability, including the presence of a
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at least 3 cm in length, the absence of extensive aneurysmal
or stenotic disease at the level of the iliac and femoral
arteries, and the presence of at least one good tibial or
peroneal artery serving as a run-off vessel.
2. Some patients with aneurysms presented with acute limb
ischemia. These patients with an acute occlusion of a PAA
butwith a viable limb (Rutherford category I and IIa acute
limb ischemia)12 were usually treated by thrombolysis.
After successful recanalization, they were evaluated for
endovascular repair as in an elective setting.
This study was approved by the institutional medical ethics
committee, and each patient provided informed consent.
Endovascular procedure. On admission, duplex ul-
trasound scanning was performed to determine intima-to-
intima diameters of landing zones and length of the aneu-
rysm. In addition, the proximal and distal margins of the
aneurysm were marked with a pencil on the patient’s leg. In
the presence of mural thrombus, this proved to be a reliable
indication of the exact localization of the aneurysm.
All procedures were performed in an operating theater by
an endovascular team that included a vascular surgeon and a
radiologist. Access to the ipsilateral common femoral artery
was achieved by open dissection of the groin. A 30-cm-long
12F sheath was introduced and continuously flushed with
heparinized saline (500 IU/500 mL). Heparin (5,000 IU)
was also administered intravenously. A calibrated straight an-
giocatheter was positioned just proximal to the trifurcation of
the popliteal artery, after which angiography was performed
by hand injection through the sheath.
The selection of the appropriate stent graft was based
upon measurements of landing zone diameters and lengths.
Both preoperative duplex ultrasound scanning and intraoper-
ative calibrated angiography were used in the decision-mak-
ing. Self-expanding nitinol-supported stent grafts with an
inner lining of ultrathin expanded polytetrafluoroethylene
Table I. Literature overview of popliteal artery aneurysms
Author
Publication
Year
No. of
aneurysms
Type of ste
(No. pe
Marcadé13 1996 6 CE
Kudelko14 1998 1 WG
Bürger15 1998 1 HB
Beregi16 1999 3 CE
Müller-Hülsbeck17 1999 6 CES(4); P(
Henry18 2000 10 P(7); CO
Ihlberg19 2000 1 HB
Howell20 2002 13 WG
Gerasimidis21 2003 9 HB(6); WG
This study 2005 57 HB; V
CES, Cragg Endopro system 1; WG, Wallgraft; HB, Hemobahn; P, Passage
*Reports on homemade devices were not included.
†In some patients both the Hemobahn and Viabahn stent-graft were use
according stent-grafts.
‡Not stated in the article.(PTFE) were used. Up to June 2003, only the Hemobahnstent graft (W.L. Gore & Associates, Inc, Flagstaff, Ariz) was
used. After June 2003, the Viabahn stent graft (W.L. Gore)
also became available and was used instead of the Hemobahn
for the available diameters of 6, 7, and 8 mm. Technical
improvements of theViabahn included the deployment over a
0.035-inch instead of a 0.025-inch guide wire, concentric
deployment instead of unfolding, and deployment starting at
the distal end instead of the proximal end in the Hemobahn,
providing an easier and more accurate deployment distally.
Follow-up. In an effort to avoid kinking of the stent
graft, our patients were advised to avoid90° knee flexion.
Ankle brachial pressure index (ABI), duplex ultrasound
scanning, and plain radiographs of the knee were made at
discharge, after 6 weeks, and every 6 months thereafter.
Radiographs of the knee were made in extension, including
both anteroposterior and lateral views, and in 90° flexion.
All patients received antiplatelet or anticoagulation ther-
apy. Up to April 2003, antiplatelet therapy consisted of 80
mg/day acetylsalicylic acid (ASA). After April 2003, this
protocol was changed and 75mg clopidogrel was added for
6 weeks after the operation. Patients who were taking
anticoagulants before the intervention, mostly for cardiac
indications, continued this therapy after the operation.
These patients were also given clopidogrel for 6 weeks.
Definitions. Quality of arterial outflow was assessed on
preoperative angiography and reported by the number of
peroneal and tibial arteries that were patent up to the ankle.
The total stented length was defined as the total length of the
popliteal artery covered by the stent graft, measured on plain
radiograph of the knee. This equals the sum of the length of
the stent grafts used, minus the sum of the length of the
overlap zones.The available stent graft lengthswere 5, 10, and
15 cm; therefore, more than one stent-graft was needed in
some cases. The overlap zone was defined as the extent of
insertion of one stent-graft into the other. The landing zone
was defined as the site of healthy popliteal artery where the
ted with commercially available stent-grafts*
aft
)
No. treated
emergently for
acute
ischemia (%)
Follow-up
period
(mo; mean)
Occlusions
(No. per type) (%)
0 6 1
0 10 0
1 6 0
0 24 0
S(1) 6 (100) 4 4 (3CES; 1P) (67)
3) —‡ —‡ 5 (3CORV; 2P) (50)
0 5 0
0 12 4
P(1) 0 14 4 (3HB; 1WG) (44)
5 (9) 24 12 (21)
, Wallstent; CORV, Corvita; VB, Viabahn.
reat the popliteal aneurysm according to the diameters and availability oftrea
nt-gr
r type
S
S
1); W
RV(
(2);
B†
r; WS
d to tstent-grafts ended proximally and distally to the PAA. A
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cluded with preservation of the outflow vessels.
Statistical analysis. Data for continuous variables were
expressed as mean  standard deviation. Data were prospec-
tively collected and analyzed in a retrospective manner. Pri-
mary outcomemeasures were graft patency, limb survival, and
patient survival. Time-to-event variables were studied with
Kaplan-Meier survival analysis using the Statistical Package for
the Social Sciences (SPSS) version 11.0 software (SPSS, Chi-
cago, Ill). The predictive value of the different variables on
occlusion of the stent graft was assessed in univariate analyses.
Categorical variables were analyzed with 2 test and continu-
ous variables were analyzed with the Student t test (normal
distribution) or Mann-WhitneyU test (skewed distribution).
Significant factors of the univariate analyses were entered in a
logistic regression model. P .05 was considered statistically
significant.
RESULTS
A total of 67 PAA in 57 patients were evaluated for
endovascular repair. Ten PAA were excluded from endo-
vascular repair by the selection criteria (Table II). The
remaining 57 PAAs (85%) in 48 patients were treated
endovascularly. The mean age of these patients was 66 9
years (range, 52 to 85 years), and 91% were men. Twelve
(21%) of the 57 PAAs were symptomatic and presented
with acute ischemia (n  5), venous compression (n  3),
claudication (n 2), pain in the popliteal fossa (n 1), or
rupture (n  1). Six patients were treated in an acute
setting, of whom five presented with acute limb ischemia.
They were treated with thrombolytic therapy (urokinase)
and subsequent stent grafting. The other patient had a
ruptured aneurysm. The mean PAA diameter was 29  8
mm (range, 16 to 65 mm). Two smaller aneurysms (16 and
Table II. Details of patients excluded for endovascular
repair
Exclusion criteria n Treatment
Elective cases
Inflow disease 2 Below-knee bypass
Outflow disease* 3 Below-knee bypass
Combination of in/outflow
disease
1 Below-knee bypass
Thrombosis of the aneurysm 2 No treatment†
Acute cases
Thrombosis of the
aneurysm
2 Below knee bypass
(1) / No
treatment‡ (1)
Total 10
*One patient had a high anterior tibial artery origin; two patients had a
too-short distal landing zone.
†Thrombosis diagnosed on day of planned endovascular treatment; no
treatment because asymptomatic.
‡Patient presented with marginally threatened acute limb ischemia (Ruther-
ford category II.a)12 with evolution to moderate claudication in a few days
time. He was not treated because of extensive comorbidity, including
impaired renal function.18mm) occurred in two of the patients who presented withacute limb ischemia. All repairs were technically successful.
Details of the operative procedures are listed in Table III.
During a mean follow-up of 24 months (1 to 72), 12
stent grafts occluded (21%). Thrombolytic therapy was
used to recanalize these occluded vessels in 7 patients, open
thrombectomy was performed in 1 patient, and the other 4
were managed conservatively (Table IV). Thrombolytic
therapy failed in two of the seven patients, and additional
thrombectomy was then performed. No patient required
amputation or bypass surgery.
Primary and secondary patency rates were 80% and 90%
at 1 year, and 77% and 87% at 2 years follow-up, respec-
tively (Figure 1). None of the stent grafts occluded in the
emergent group.
At univariate analysis, treatment with clopidogrel was the
only significant predictor for success (n 18, patency 100%)
(P .008). Age of the patient, diameter of the aneurysm, type
of stent graft, number and length of endoprostheses, length of
overlap zone, number of run-off vessels (one vs two or three),
and type of surgery (elective vs emergent), were not. In a
multivariate logistic regression, the effect of clopidogrel intake
was again found to be the only significant predictor for success
Table III. Details of operative procedures
n %
Preoperative
Grade of outflow quality
(number of infrapopliteal
vessels)
1 4 7
2 14 25
3 39 68
Thrombolytic therapy 5 9
Intraoperative
Approach
EIA* 1 2
CFA 56 98
No. of stent grafts per aneurysm
1 18 32
2 32 56
3 6 10
4 1 2
Patients treated bilaterally in
one session 6 10
Ancillary procedures:
Aortic bifurcation graft 1
Interposition graft CFA 5
PTA SFA 1
Total 7 12
Postoperative
Antiplatelet therapy
with/without clopidogrel
17/33
Anticoagulation with/without
clopidogrel
1/6
Antiplatelet therapy or
anticoagulation
with/without clopidogrel
18/39 32/68
CFA, Common femoral artery; EIA,: external iliac artery; SFA, superficial
femoral artery; PTA, percutaneous transluminal angioplasty.
*Treated with an aortobiiliac prosthesis for abdominal aortic aneurysm in
the same session.(2[1] 10.526, P .01).
al an
enosis
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the prosthesis, stenosis at the border of the stent graft,
continuous sac enlargement, and breakage of the stent
material (Table V). Early migration led to the disconnec-
tion of two overlapping stent grafts and a type III endoleak
in one patient. Diagnosis was made on the first postopera-
Table IV. Details of 12 occlusions
Patient
Number
Age
(y)
Time to
occlusion
(months)
Symptoms*
(Rutherford)12 Treatment R
1 82 6 Claudication (2) –
2 82 6 Acute ischemia (IIb) –†
3 72 6 Acute ischemia (IIa) Thrombectomy
4 78 1 Acute ischemia (IIa) Thrombolysis‡
5 55 9 Claudication (2) –
6 59 1 Acute ischemia (IIa) Thrombolysis§
7 68 28 Claudication (2) –
8 53 1 Acute ischemia (IIa) Thrombolysis
9 75 1 Acute ischemia (IIa) Thrombolysis
10 66 23 Claudication (3) Thrombolysis
11 61 10 Claudication (3) Thrombolysis**
12 63 1 Acute ischemia (IIa) Thrombolysis††
*Rutherford classification for acute limb ischemia (I, IIa, Iib, and III) and
†Occlusion of Hemobahn following occlusion of iliac inflow tract (Vangu
without additional treatment to recanalize the occluded Hemobahn.
‡Thrombolysis followed by iliac artery and superficial femoral artery PTA an
§Thrombolysis followed by Wallstent to cover a fold in the proximal end of
**Thrombolysis failed and was followed by open thrombectomy and proxim
††Thrombolysis followed by stent at the proximal border of the stent for st
Fig 1. Cumulative primary and secondary patency rates
7.8% for primary and secondary patency, respectively.tive day with radiograph, and repair with a bridging stentgraft was successful. In two other patients, the sealing zone
initially chosen was short, and a slight late migration oc-
curred that led to a type I endoleak. Repair with an exten-
sion was successful. Stenosis at the border of the stent graft
occurred in two patients. One of these patients presented
with claudication after 12 months and was successfully
sion Treatment
Residual symptoms*
(Rutherford)12 Status
Follow-up
(months)
– Claudication (1) Occluded 65
– Claudication (2) Occluded 56
s No Claudication (3) Occluded 51
s No Claudication (3) Occluded 45
– Claudication (2) Occluded 45
– Asymptomatic (0) Open 41
– Claudication (2) Occluded 55
s No Claudication (3) Occluded 24
– Asymptomatic (0) Open 20
s Thrombectomy Claudication (1) Open 40
– Claudication (1) Open 20
s No Claudication (3) Occluded 2
onic limb ischemia (0 to 6).
ntralateral limb), treated with crossover bypass to the deep femoral artery
t.
emobahn.
d distal patch plasty.
.
dard errors ranged from 1.7% to 7.7% and from 1.8% toeocclu
–
–
Ye
Ye
–
No
–
Ye
No
Ye
No
Ye
for chr
ard co
d sten
the H. Stantreated with percutaneous transluminal angioplasty (PTA).
 of onl
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was diagnosed on angiography during repair for a proximal
endoleak. Treatment with PTA was successful. Breakage of
the stent material was observed in two patients, which led
to occlusion in both cases.
During follow-up, five patients died of unrelated causes
after a mean of 40  20 months after the procedure. The
1-year and 2-year patient survival was 100% and 97%.
DISCUSSION
This prospective cohort study shows that the results of
endovascular treatment of PAA are slightly inferior to those of
open repair. The primary patency rate was 77% at 2 years of
follow-up. Complications occurred in 21 (37%) of the 57
treated aneurysms and included occlusions, stenoses, migra-
tions, endoleaks, and continuous sac enlargement. Twelve
stent grafts (21%) occluded, but no patient with an occluded
stent-graft needed a femoropopliteal bypass or an amputation.
We believe this is the largest series of PAA treated with
one type of endovascular stent graft. The Hemobahn and the
Viabahn, which were used in this series, are made of a nitinol
stent with an inner lining of ultrathin (100 m) expanded
PTFE. The advantages of these stent grafts over other designs
may be that they have a high flexibility, which is necessary to
cross the knee joint, and that the luminal surface is made of
smooth graft material instead of irregular stent material.
A literature search of reports on endovascular treatment
for PAA with commercial devices only reveals case reports and
small series (Table I).13-21 Some of these devices, including
the Cragg Endopro System 1 (Mintec, Freeport, Bahamas)
which became later the Passager stent graft (Boston Scientific,
Watertown,Mass), and the Corvita stent graft (Boston Scien-
tific, Bülach, Switzerland),were relatively stiff. Therefore, they
were not ideally designed to be used in a relatively small artery
such as the popliteal artery, which is subject to repetitive
flexion and extension. Other devices such as the Wallgraft
(Boston Scientific, Natick, Mass) and the Hemobahn/Via-
bahn are more flexible.
An advantage of theHemobahn/Viabahn, in our view, is
Table V. Complications other than occlusions
Complication n
Migration
Without endoleak 5
With type 1 endoleak 2
With type 3 endoleak* 1
Sac enlargement 1
Stenosis† 2
Stent breakage 2
Total 13 in 9 patients
PTA, Percutaneous transluminal angioplasty.
*Type 3 endoleak was diagnosed on the duplex scan on the first postoperat
†One of these two patients had an extension proximally and a PTA distally,
‡This patient had an occlusion (patient 11; Table IV).
§This patient had an occlusion (patient 7; Table IV); no treatment becausethat the graft—not the stent—is situated at the luminal sur-face. In addition, greater lengths are available. The mean
covered length in our series was 20 6 cm (range, 10 to 34).
In 70% of the cases, we used more than one stent-graft to
cover the length of the aneurysm and the two landing zones,
with landing and overlap zones that are each preferably 3 cm
long. These long overlap and landing zones are chosen to
overcome the complications of migration, which may lead to
either endoleak at the landing zone or disconnection at the
overlap zone. A diameter mismatch between proximal and
distal landing zone is another reason to use more than one
stent graft.
Several recent studies have been published showing re-
sults of open reconstruction with a femoropopliteal bypass. In
these studies, including both emergent and elective cases and
treated with either venous bypasses or prostheses, 5-year pri-
mary patency and limb salvage rates were 69% to 86% and 87%
to 98%, respectively.3,4,6,8,9,22-24 The 30-day mortality was
0% to 7.7%. In some of these studies, primary patency rates
were 82% to 92% for the subgroup of elective cases.4,6,23,24 All
studies, however, were retrospective and may have suffered
from selection bias.
Our prospective series of endovascular repair had a 2-year
primary patency rate of 77% and a limb savage rate of 100%
after a mean follow-up of 24 months. The estimated 5-year
primary patency ratewas 72%; however,with only 3 patients at
risk, comparison with open results at this time interval is
unreliable. Persistent enlargement of the aneurysm sac has
been diagnosed after open repair in 33% of the cases.22,25,26
In some, enlargement was caused by within sac flow from
feeding branches. No type II endoleak was found in our
endovascular series and only one aneurysm increased in diam-
eter during follow-up.Nogood explanation for this difference
between open and endovascular repair could be found.
Forty-two percent of occlusions (5 of 12) occurredwithin
the first month and 75% (8 of 12) within 6 months after the
operation. This may suggest an influence of the postoperative
antiplatelet therapy. Therefore, in analogy with the use in
coronary artery bypass stenting and femoropopliteal stent-
ing,27 we changed the follow-up protocol after April 2003
Treatment Status
— Patent
Extension Patent
Bridging stent-graft Patent
— Patent
PTA Patent
Thrombectomy‡(1) Patent
No treatment§ (1) Occlusion
y; radiograph showed disconnection.
 the patient with sac enlargement.
y mild claudication.ive da
 and isand added clopidogrel for 6 weeks after the operation. No
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study, the additional use of clopidogrel proved to be the only
significant predicting factor of success at univariate analysis.
Endovascular treatment of a PAA with stent grafts is a
relatively easy, minimally invasive procedure that takes about 1
hour to complete.11 A critical point leading to success, how-
ever, is the meticulous measuring of the landing zone diame-
ters. In our practice, this was best done by a dedicated vascular
technician and controlled by means of preoperative and intra-
operative calibrated angiography. Another point of attention
is to avoid placing the end of an overlap zone in the bending
zone of the knee, situated at the level of the upper margin of
the patella. This is especially truewhen the distalmargin of the
aneurysmends at the same level as the endof the overlap zone.
In two patients, this led to a stent fracture and eventually to
occlusion of the stent-graft (Table V).
In our view, the minimally invasive character of the endo-
vascular procedure is an advantage, especially in patients with
bilateral aneurysms where operation time can be saved, which
is important in a country where long waiting lists for opera-
tions exist. Thisminimally invasive approachmay be an advan-
tage in acute cases with critical ischemia because it avoids
incisions in an ischemic leg. Moreover, in cases where occlu-
sion of the stent-graft leads to invalidating claudication or
critical ischemia, a below-knee femoropopliteal bypass is still
possible. Therefore, in our hospital the endovascular proce-
dure is the first treatment option, irrespective of the availability
of saphenous vein.
CONCLUSIONS
Endovascular repair of a popliteal artery aneurysm is fea-
sible. Patency appears slightly inferior to open repair, although
most open serieswere retrospective studies. Recent changes to
the material used and the additional use of clopidogrel may
improve patency rates, however. To better understand the
potential role of this minimally invasive technique, further
studies are necessary to define the ideal indications, anatomic
andprosthetic graft limitations, and the effect of anticoagulant
and antiplatelet treatment. A randomized controlled trial
should be undertaken to fully evaluate the endovascular exclu-
sion of PAAs compared with the standard open femoropopli-
teal bypass procedure and with regard to patency and postop-
erative complications.
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